



FOR IMMEDIATE RELEASE

Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board

- James Hindman, Former Allergan CFO, Joins Board of Directors -

- Carol Gallagher, NEA Partner and Current Board Member, Named Chair -

ANN ARBOR, Mich., Jun. 23, 2016 – [Millendo Therapeutics, Inc.](#), a company developing novel therapies for endocrine diseases caused by hormone dysregulation, today announced the appointment of James Hindman as an independent board member and chairperson of its audit committee. In addition, Millendo has appointed current board member and Partner of New Enterprise Associates, Inc., Carol Gallagher, Pharm.D., as Chairperson of the Board.

“Jim brings a wealth of financial knowledge and industry experience to Millendo from his years of senior leadership in pharma and biologics,” said Julia C. Owens, Ph.D., President and Chief Executive Officer of Millendo. “We welcome Jim’s expertise as he will be instrumental in helping to shape our strategy and achieve our mission to develop and deliver disease-modifying treatments for endocrine diseases caused by hormone dysregulation.”

“Carol has been a key supporter and champion of Millendo since joining our board soon after our Series A financing,” Owens continued. “We are delighted that she has assumed the role of Chairperson and will continue her service on and leadership of the Board.”

Mr. Hindman most recently served as Executive Vice President of Finance and Business Development and Chief Financial Officer at Allergan, Inc., where, under his leadership, the company achieved its most robust financial performance in Allergan’s 64-year history. Mr. Hindman was also instrumental in facilitating the company’s largest restructuring, creating \$20B in shareholder value that ultimately led to Actavis’ acquisition of Allergan in 2015 and the creation of one of the top ten global pharmaceutical firms. During his 30-year tenure at Allergan, Mr. Hindman held various senior leadership positions including Executive Vice President of Finance and Business Development and Chief Financial Officer, and Senior Vice President, Finance and Controller, and was responsible for strategic and financial functions including treasury, investor relations, risk, controller, financial reporting, SEC compliance, audits, acquisitions and divestitures, and strategic planning. Additionally, he served as President of the Allergan Foundation from 2009-2015. Mr. Hindman earned his MBA from Pepperdine University and a B.S. in accounting from Loyola Marymount University. He currently serves as Director of NeuroSigma, Inc. and is a member of the Loyola Marymount University Board of Trustees.

“It is an honor to join the Millendo Board of Directors at such an exciting time in the Company’s growth,” said Mr. Hindman. “I look forward to working with the Millendo team to deliver novel treatment options for patients with endocrine diseases for which there are currently limited or no approved treatment options. The strength of both the company’s pipeline and leadership team are impressive and a testament to Millendo’s success thus far,” Hindman continued. “I am excited to have the opportunity to contribute my experience and expertise to the Company’s future achievements and continue to advance important new treatments for endocrine diseases.”

About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine diseases caused by hormone dysregulation. Our product candidates seek to improve the quality of life for

patients with orphan and specialty diseases with limited or no approved treatment options. Our clinical programs are designed to address:

- Polycystic Ovary Syndrome (PCOS) – the most common endocrine disease in women
- Congenital Adrenal Hyperplasia (CAH) – a recessive genetic defect of cortisol synthesis
- Endogenous Cushing's Syndrome (CS) – a condition resulting from chronic cortisol excess
- Adrenocortical Carcinoma (ACC) – a rare endocrine malignancy of the adrenal cortex

Our experienced team is committed to bringing these first-in-class therapies to market.

www.millendo.com

###

Media Contact:

Blair McCarthy Atkinson
MacDougall Biomedical Communications
Main: +1 781 235 3060
Direct: +1 812 454 6257
batkinson@macbiocom.com

Investor Contact:

Stephanie Ascher
Stern Investor Relations
+1 212 362 1200
stephanie@sternir.com